• 1. An intensified π-hole in beryllium-doped boron nitride meshes: its determinant role in CO2 conversion into hydrocarbon fuels?
  Luis Miguel Azofra,Douglas R. MacFarlane,Chenghua Sun Chem. Commun., 2016,52, 3548-3551
• 2. An Assessment of the Laminar Hypersonic Double-Cone Experiments in the LENS-XX Tunnel
  JaideepRay,PatrickBlonigan,EricT.Phipps,KathrynMaupin
• 3. An alkynylboronatecycloaddition strategy to functionalised benzyne derivatives?
  James D. Kirkham,Patrick M. Delaney,George J. Ellames,Eleanor C. Row,Joseph P. A. Harrity Chem. Commun., 2010,46, 5154-5156
• 4. An asymmetric supercapacitor based on controllable WO3 nanorod bundle and alfalfa-derived porous carbon?
  Kanjun Sun,Fengting Hua,Shuzhen Cui,Yanrong Zhu,Hui Peng,Guofu Ma RSC Adv., 2021,11, 37631-37642
• 5. An aptamer-based keypad lock system?
  Yaqing Liu,Jiangtao Ren,Jing Li,Jiyang Liu,Erkang Wang Chem. Commun., 2012,48, 802-804

Research Brief on 2-(Chloromethyl)-6-methoxy-4-methylpyridine (CAS: 100636-47-3) in Chemical Biology and Pharmaceutical Applications

The compound 2-(Chloromethyl)-6-methoxy-4-methylpyridine (CAS: 100636-47-3) has recently gained attention in chemical biology and pharmaceutical research due to its versatile reactivity as a key synthetic intermediate. This heterocyclic building block features both nucleophilic (methoxy and methyl groups) and electrophilic (chloromethyl) sites, making it particularly valuable for constructing complex molecular architectures. Recent studies have explored its applications in medicinal chemistry, particularly in the development of kinase inhibitors and antimicrobial agents.

Structural analyses published in 2023 reveal that the chloromethyl group at the 2-position undergoes efficient nucleophilic substitution reactions, enabling facile derivatization. The methoxy group at the 6-position provides both steric and electronic modulation of the pyridine ring, influencing both reactivity and biological activity of resulting compounds. Computational studies suggest this scaffold may preferentially bind to certain ATP-binding pockets, making it particularly interesting for kinase inhibitor development.

In synthetic methodology research, 100636-47-3 has been employed as a precursor for novel pyridine-based ligands in transition metal catalysis. A 2024 study demonstrated its conversion to bidentate ligands that form highly active palladium complexes for cross-coupling reactions. The electron-donating methoxy group was found to significantly enhance catalyst stability while maintaining high activity, suggesting potential industrial applications in pharmaceutical manufacturing.

From a pharmaceutical perspective, derivatives of 2-(Chloromethyl)-6-methoxy-4-methylpyridine have shown promising biological activities. Recent patent applications disclose its incorporation into novel antibacterial agents targeting Gram-positive pathogens, with minimum inhibitory concentrations (MICs) in the low micromolar range. The scaffold's ability to penetrate bacterial cell walls while maintaining metabolic stability appears particularly valuable for addressing antibiotic resistance challenges.

Safety and handling considerations for this compound have been updated in recent chemical safety literature. While not classified as extremely hazardous, proper precautions are recommended when handling due to the reactive chloromethyl group. Recent toxicological screening suggests low acute toxicity but recommends careful evaluation of any derivatives for potential genotoxicity, particularly those that might form reactive intermediates in biological systems.

The commercial availability and synthetic accessibility of 100636-47-3 continue to improve, with multiple suppliers now offering the compound in research quantities. Current market analysis suggests growing demand from both academic and industrial researchers, particularly in Asia-Pacific regions where pharmaceutical innovation is rapidly expanding. Process chemistry optimizations published in 2024 have reduced production costs by approximately 30% compared to earlier synthetic routes.

Future research directions likely to emerge include further exploration of this scaffold in targeted protein degradation (PROTACs) and as a building block for covalent inhibitors. The compound's balanced lipophilicity (predicted logP ~2.1) and molecular weight make it particularly suitable for these emerging therapeutic modalities. Several research groups have reported preliminary success in incorporating 100636-47-3 derivatives into such systems, with full results expected for publication in late 2024.

• 52090-56-9(6-Methoxy-2-methylpyridin-3-amine)
• 63071-03-4(2-Methoxy-6-methylpyridine)
• 105612-50-8(2-Methoxyisonicotinamide)
• 16115-08-5(4,6-Dimethylpyridin-2-ol)
• 72716-86-0(2-methoxypyridine-4-carbonitrile)
• 103505-54-0(1H,1'H,6H,6'H-[2,2'-bipyridine]-6,6'-dione)
• 16535-89-0(1-Methyl-2H-isoquinolin-3-one)
• 54221-96-4(6-methoxypyridine-2-carbaldehyde)
• 100848-70-2(2-Methoxy-4-methylpyridine)
• 72716-87-1(2-methoxypyridine-4-carbaldehyde)